Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NIH × raltitrexed × Clear all
NCT00003528 2013-01-16

Raltitrexed in Treating Children With Refractory Acute Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00001341 2008-03-04

A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡